← Browse by Condition
Medical Condition
fibrillary glomerulonephritis
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT06295770 Phase 2
Recruiting
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Enrollment
20 pts
Location
United States
Sponsor
Mayo Clinic
NCT06065852
Recruiting
National Registry of Rare Kidney Diseases
Enrollment
35,000 pts
Location
United Kingdom
Sponsor
UK Kidney Association